Biocon bets on generics, biosimilars

Biocon expects mid-to-high teens growth for its generics and biosimilars businesses in this fiscal year

- Jessica Jani

Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in its generics as well as biosimilars businesses to drive sales in the coming years, its chief executive officer and managing director Siddharth Mittal said on Tuesday.

The Bengaluru-based company expects mid-to-high teens growth for its generics as well as biosimilars businesses in FY26. The company's listed contract development and manufacturing organization (CDMO) arm Syngene is likely to report revenue growth in the mid-single digits this fiscal year, the company's management has guided. "At a company level, you are looking at a blended mid-teens growth," Mittal told Mint.